Baird analyst Eric Coldwell raised the firm’s price target on Cardinal Health to $108 from $107 and keeps an Outperform rating on the shares. The firm said strong Pharmaceutical performance continues to drive results, while green shoots are evident regarding improving Medical profitability towards FY26 $650M AOI objective, driven by management’s improvement plan and easier comps.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH:
- Cardinal Health (NYSE:CAH) Stock Down Despite Positive Q4 Results
- Cardinal Health raisesFY24 EPS view to $6.50-$6.75 from $6.45-$6.70
- Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2023 at High End of Investor Day Guidance
- Cardinal Health reports Q4 EPS $1.55, consensus $1.49
- Notable companies reporting before tomorrow’s open